Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Next gen RNA sequencing of mouse acute myeloid leukemia
PubMed Full text in PMC Similar studies SRA Run Selector
Leukemia stem cell-enriched population expresses self-renewal gene-expression signature [RNA-Seq]
NRASG12V oncogene mediates self-renewal in acute myelogenous leukemia
PubMed Full text in PMC Similar studies Analyze with GEO2R
NRASG12V mediates leukemia self renewal [RNA-Seq]
NRASG12V mediates self renewal in AML [RNA-Seq]
NRASG12V mediates leukemia self renewal [Microarray]
TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity
PubMed Full text in PMC Similar studies
Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity [bisulfite-Seq]
Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity [RNA-Seq]
A gain-of-function p53 mutant synergizes with oncogenic Nras to promote acute myeloid leukemia in mice
Assessment of MEK-ERK pathway targeting by BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias
Assessment of MEK-ERK pathway targeting by BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias [U266 human myeloma cell line]
Assessment of MEK-ERK pathway targeting by BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias [Patient samples]
B11 cells created by replacing the NRAS-G12D mutation in THP1 cells with a dox-inducible NRAS-G12V mutation
Wild-Type Nras Lacks Tumor Suppressor Activity and Nras Oncogene Dosage Strongly Modulates Hematopoietic Transformation
Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukaemia by whole genome sequencing
Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia
Expression data from second oncogene expressing Melanoma Cells.
Analysis of SKMEL-103, AsPC1 and RH-36 cells after treatment with BAY 11-7082
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on